Adverse events affecting ≥5% of patients in either group
Hyperkalemia, nasopharyngitis, arthralgia, back pain, urinary tract
infection, diarrhea, anemia, hypertension, upper respiratory tract
infection, peripheral edema, decreased GFR, hypoglycemia, dizziness,
bronchitis, constipation, and pneumonia were adverse events affecting
5% of patients in either group. Patients treated with Finerenone had an
increased risk of hyperkalemia, anemia, decreased eGFR, dizziness, upper
respiratory tract infection, diarrhea, and arthralgia, but a decreased
risk of hypoglycemia, pneumonia, peripheral edema, constipation, UTI,
bronchitis, nasopharyngitis, and hypertension. Table 3 details the
adverse events that affected five percent of the population.